These findings enhance our understanding of ICC pathogenesis and reveal a novel cross‐talk mechanism between inflammation and tumorigenesis in cancer as well as establish FXYD3 as a highly promising diagnostic marker, prognostic indicator, and therapeutic target, paving a new path for precision therapy in ICC. The gene discussed is FXYD3; the disease is cancer.